A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of Cell [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for cancer: Tumor suppressor p53 increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation in cancer via down regulation of its target gene. This study suggests, for the first time, that Guardian of the genome p53, by suppressing the expression of its target gene, it may : (1) increase the expression of tumor suppressor PTX2; and (2) inhibit complement-dependent tumor inflammation in cancer. Together, pharmacological formulations encompassing “p53 activators” may be used to treat inflammation-associated cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for cancer: Tumor suppressor p53 increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation in cancer via down regulation of its target gene, 27/February/2015, 9.07 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Undisclosed information: How p53 increases the expression of tumor suppressor PTX2